Search

Displaying results 2841 - 2850 of 7503 in total
  1. Drug

    Pagoclone

    go.drugbank.com/drugs/DB04903
    Investigational

    It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures … Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone.

  2. Drug

    Clopamide

    go.drugbank.com/drugs/DB13792
    Investigational

    Like thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.

  3. Drug

    Lithium carbonate

    go.drugbank.com/drugs/DB14509
    ApprovedInvestigational

    Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. … Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup a capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae

  5. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  6. Drug

    ONO-2952

    go.drugbank.com/drugs/DB14802
    Investigational

    ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable

  7. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

  8. Drug

    Thiocolchicoside

    go.drugbank.com/drugs/DB11582
    Investigational

    It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]

  9. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875] … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

    Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
  10. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.